Connect with us

Technology

Lindus Health and Aktiia to launch observational clinical trial for Aktiia’s Optical Blood Pressure Monitoring Device

Published

6 months ago

on

NEW YORK, July 9, 2024 /PRNewswire/ — Lindus Health, the “anti-CRO” running radically faster, more reliable clinical trials for life science pioneers, and Aktiia, the pioneering blood pressure intelligence startup offering non-invasive and cuffless continuous blood pressure monitoring, have announced the launch of their clinical trial to evaluate user satisfaction with Aktiia’s optical blood pressure monitoring (OBPM) device in hypertensive individuals.

Hypertension, or high blood pressure, is estimated to affect over 1.3 billion adults globally, and is the leading cause of heart disease, stroke, kidney disease, and many other diseases. Devices that continuously monitor blood pressure can offer valuable insights into hypertension severity, treatment efficacy, and fluctuations related to daily activity, lifestyle, and sleep patterns.

This study will examine user experience with Aktiia’s non-invasive, cuffless OPBM device. The device, worn as a bracelet, measures blood pressure continuously using optical sensors, offering a more convenient alternative to traditional blood pressure cuffs. In addition to measuring satisfaction with the device, the trial will also observe the evolution of participants’ blood pressure over the study period and correlate this data with sociodemographic, lifestyle, and health factors.

Lindus Health and Aktiia will enroll 7,500 participants with known hypertension in this 12-week clinical trial. Lindus Health will provide end-to-end study management, including protocol development, regulatory submissions, recruitment, monitoring, and data management. They will utilize their in-house virtual site and digital marketing capabilities for patient recruitment through digital advertising as well as primary care screening and patient community outreach. A dedicated study website will be developed with relevant trial information and integrated with Lindus Health’s proprietary eClinical platform, Citrus™, to enable candidates to seamlessly complete pre-screening and eConsent.

“Lindus Health is incredibly humbled to be collaborating on the Aktiia trial, where we’ll have the ability to provide thousands of individuals with continuous visibility on their blood pressure on a continuous basis,” said Michael Young, co-founder at Lindus Health. “Hypertension greatly burdens both patients and healthcare systems and there is an evident need for technologies that effectively help individuals manage chronic diseases while seamlessly integrating with their everyday lives.”

“Aktiia’s technology gives individuals greater autonomy to better manage their health,” said Dr. Jay Shah, Chief Medical Officer at Aktiia. “Our device and smartphone application allow patients and providers to understand their blood pressure patterns and changes in real-time, making it easier to pinpoint causes for fluctuations. We’re excited and proud to be working with Lindus Health to deliver blood pressure intelligence to patients with hypertension to help them better manage their condition.”

Favorable outcomes pertaining to user experience will underscore the value in developing wearable devices to continuously monitor, manage, and prevent chronic diseases that are both accurate and comfortable.

About Lindus Health

Lindus Health is an anti-CRO running radically faster and more reliable trials for life science pioneers – bringing ground-breaking treatments to patients more quickly. This is achieved through a commercial model that aligns incentives (fixed-priced quotes per study, with milestone-based payments), a world-class clinical operations team with its unique software platform, and access to over 30 million Electronic Health Records.

Clinical trials are the biggest bottleneck to advances in healthcare. Lindus Health removes this constraint by handling the end-to-end execution of clinical studies, including design, patient recruitment, clinical data capture, monitoring and project management.

To date, Lindus Health has delivered more than 90 trials across the US, UK and Europe to tackle a range of conditions, including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. The company has raised over $24M from investors including Peter Thiel, CREANDUM, Firstminute Capital, Presight Capital, Seedcamp, Hambro Perks, Amino Collective and Calm/Storm.

About Aktiia

Founded in Switzerland in May 2018, Aktiia was created out of a passion to develop the best
products for diagnosing and treating hypertension. Founders Drs. Mattia Bertschi (CEO) and Josep Solà (CTO) spent 15 years at the prestigious Swiss research institute CSEM, deciphering the language of the heart and blood vessels to deepen our understanding of blood pressure – the world’s most common risk factor of death and disease.

Today, Aktiia’s diverse team of over 50 extraordinary individuals is transforming years of innovative research into a global healthcare solution, offering the most complete and intuitive blood pressure monitoring and management tools on the market.

https://aktiia.com
Media contact: press@aktiia.com

Lindus Health Media Contact:
Jodi Perkins
Amendola for Lindus Health
jperkins@acmarketingpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lindus-health-and-aktiia-to-launch-observational-clinical-trial-for-aktiias-optical-blood-pressure-monitoring-device-302191705.html

SOURCE Lindus Health

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

TriNetX’s Founding CEO Announces Plans to Step Down

Published

18 minutes ago

on

January 9, 2025

By

After 11 Years, Gadi Lachman to Conclude Operating Role, Remain on TriNetX’s Board

CAMBRIDGE, Mass., Jan. 9, 2025 /PRNewswire/ — TriNetX, the largest global source of real-world data, today announced that Gadi Lachman, the Company’s Founder, President and CEO, will step down from his operating role on March 31, 2025. Gadi founded TriNetX in 2014 and has served as President and CEO in the succeeding 11 years. Gadi will continue to serve on TriNetX’s Board of Directors and will be an Advisor to Carlyle, TriNetX’s majority investor.

“It has been an honor to build TriNetX and be part of such an outstanding team. I want to thank TriNetX’s employees, customers, and shareholders for the support they have shown me. With the talent and passion of our people I am immensely confident in TriNetX’s continued success,” said Lachman. “Together, we have built the largest global platform for clinical research, with data from over 25 countries and tens of millions of queries a month. Our solutions are moving clinical research to a whole different level and saving lives on a massive scale, across all therapeutic areas.”

During the transition period, Jeff Margolis, a current TriNetX Director, will serve as Executive Chairman to ensure continuity in leadership and governance while a CEO search is conducted.

Margolis said, “I have had the distinct privilege of serving on the Board alongside Gadi and partnering with him for 11 years. On behalf of the Board, we thank Gadi for shaping and leading TriNetX to become the world’s top ecosystem of real-world data and real-world evidence serving life sciences and the broader healthcare industry. I look forward to working with him and the rest of the Board over the next months to execute a successful transition of leadership.”

Joe Bress, Partner and Global Co-Head of Healthcare for Carlyle, TriNetX’s lead investor, added, “We have been thrilled to partner with Gadi since our initial investment in TriNetX over four years ago. Thanks to his disciplined leadership, TriNetX is one of the few companies that has sustained profitability even during periods of high growth. Gadi has built the company up to an exciting point, paving the way for a new leader to take the business into its next chapter of growth and success.”

Through this leadership transition, TriNetX remains steadfast in its mission to advance global healthcare through the power of real-world data. The Board, leadership team, and employees are united in their commitment to driving continued innovation and delivering success for customers and partners, all while building on Gadi’s exceptional legacy.

About TriNetX, LLC

TriNetX is a global network of healthcare organizations and life sciences companies dedicated to advancing real-world research and expediting the development of new therapies. Through its self-service, HIPAA-, GDPR-, and LGPD-compliant platform of federated deidentified and anonymous electronic health record datasets and consulting partnerships, TriNetX empowers its global community to improve clinical trial protocol design, streamline trial operations, refine safety signals, and enrich real-world evidence generation. For more information, please visit TriNetX at www.trinetx.com or follow TriNetX on LinkedIn.

Media Contact
TriNetX
Michelle Fleming, Chief Marketing Officer
Email: Michelle.Fleming@TriNetX.com

Logo – https://mma.prnewswire.com/media/542641/TriNetX_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/trinetxs-founding-ceo-announces-plans-to-step-down-302347367.html

Continue Reading

Technology

Stellus Private Credit BDC Announces $0.36 First Quarter 2025 Regular Dividend, Payable Monthly in Increments of $0.12 in January, February, and March 2025

Published

18 minutes ago

on

January 9, 2025

By

HOUSTON, Jan. 9, 2025 /PRNewswire/ — Stellus Private Credit BDC (“the Company”) announced that its Board of Trustees has declared a monthly dividend of $0.12 for each of January, February, and March, totaling $0.36 per share in the aggregate for the first quarter of 2025. The regular dividend of $0.36 per share will be paid to shareholders of record in January, February, and March 2025.

Summary of First Quarter 2025 Regular Monthly Dividends

Declared

Record Date

Payment Date

Amount per Share

1/9/2025

1/10/2025

1/31/2025

$0.12

1/9/2025

2/3/2025

2/28/2025

$0.12

1/9/2025

3/3/2025

3/31/2025

$0.12

About Stellus Private Credit BDC

The Company is an externally-managed, closed-end, non-diversified investment management company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended. The Company’s investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation by investing primarily in private middle-market companies (typically those with $5.0 million to $50.0 million of EBITDA (earnings before interest, taxes, depreciation and amortization)) through first lien (including unitranche) loans, second lien loans and unsecured debt financing, with corresponding equity co-investments. The Company’s investment activities are managed by its investment adviser, Stellus Private BDC Advisor, LLC.

Forward-Looking Statements

Statements included herein may contain “forward-looking statements” which relate to future performance or financial condition. Statements other than statements of historical facts included in this press release, including statements about COVID-19 and its impacts, may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of assumptions, risks and uncertainties, which change over time. Actual results may differ materially from those anticipated in any forward-looking statements as a result of a number of factors, including those described from time to time in filings by the Company with the Securities and Exchange Commission including the final prospectus that will be filed with the Securities and Exchange Commission. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Contacts
Stellus Private Credit BDC
W. Todd Huskinson, Chief Financial Officer
(713) 292-5414
thuskinson@stelluscapital.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/stellus-private-credit-bdc-announces-0-36-first-quarter-2025-regular-dividend-payable-monthly-in-increments-of-0-12-in-january-february-and-march-2025–302347311.html

SOURCE Stellus Private Credit BDC

Continue Reading

Technology

MongoDB, Inc. to Present at the 27th Annual Needham Growth Conference

Published

18 minutes ago

on

January 9, 2025

By

NEW YORK, Jan. 9, 2025 /PRNewswire/ — MongoDB, Inc. (NASDAQ: MDB) today announced that Chief Operating Officer and Chief Financial Officer, Michael Gordon, and Senior Vice President of Finance, Serge Tanjga, will present virtually at the 27th Annual Needham Growth Conference.

The MongoDB presentation is scheduled for Thursday, January 16, 2025, at 3:45 p.m. Eastern Time. A live webcast of the presentation will be available on the Events page of the MongoDB investor relations website at https://investors.mongodb.com/news-events/events. A replay of the webcast will also be available for a limited time.

About MongoDB
Headquartered in New York, MongoDB’s mission is to empower innovators to create, transform, and disrupt industries by unleashing the power of software and data. Built by developers, for developers, MongoDB’s developer data platform is a database with an integrated set of related services that allow development teams to address the growing requirements for today’s wide variety of modern applications, all in a unified and consistent user experience. MongoDB has tens of thousands of customers in over 100 countries. The MongoDB database platform has been downloaded hundreds of millions of times since 2007, and there have been millions of builders trained through MongoDB University courses. To learn more, visit mongodb.com.

Investor Relations
Brian Denyeau
ICR for MongoDB
646-277-1251
ir@mongodb.com

Media Relations
MongoDB PR
press@mongodb.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/mongodb-inc-to-present-at-the-27th-annual-needham-growth-conference-302347475.html

SOURCE MongoDB, Inc.

Continue Reading

Trending